Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

PBSC Donors

Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development

Bone Marrow Transplantation volume 30, pages 661–663 (2002)Cite this article

Abstract

Data on the long-term safety of filgrastim administration in peripheral blood progenitor cell (PBPC) donors are scarce. The main theoretical risk is believed to be the possible development of leukemia. We conducted a survey of filgrastim-treated related donors to determine the incidence of leukemia after PBPC donation. Of the 343 PBPC donors eligible for inclusion in the survey, 281 (82%) were interviewed by telephone between December 1998 and February 2000. The mean age at donation was 44 years. The median time elapsed after PBPC donation was 39 months, and in 278 (99%) of the interviewed donors it was at least 1 year. At the time of the interview none of the donors had been diagnosed with acute or chronic leukemia. Although the sample size is small and the follow-up duration is limited, these data suggest that exposure to filgrastim is not associated with any notable risk of leukemia development in PBPC donors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Russell N, Gratwohl A, Schmitz N . Developments in allogeneic peripheral blood progenitor cell transplantation Br J Haematol 1998 103: 594 600

    Article  CAS  PubMed  Google Scholar 

  2. Goldman J . Peripheral blood stem cells for allografting Blood 1995 85: 1413 1415

    CAS  PubMed  Google Scholar 

  3. Fischer J, Frick M, Kiesel U et al. Primary unrelated allografting with G-CSF mobilized PBPC: experience with 100 donations out of one single institution Blood 1998 92: 723a (Abstr.)

    Google Scholar 

  4. Demetri GD, Griffin JD . Granulocyte colony-stimulating factor and its receptor Blood 1991 78: 2791 2808

    CAS  PubMed  Google Scholar 

  5. Cavallaro AM, Lilleby K, Majolino I et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor Bone Marrow Transplant 2000 25: 85 89

    Article  CAS  PubMed  Google Scholar 

  6. Stroncek D, Clay ME, Herr G et al. Blood counts in healthy donors one year following the collection of G-CSF mobilized stem cells and the results of a second mobilization and collection Transfusion 1997 37: 304 308

    Article  CAS  PubMed  Google Scholar 

  7. Storek J, Dawson MA, Maloney DG . Normal T, B, NK cell counts in healthy donors at 1 year after blood stem cell harvesting Blood 2000 95: 2993 2994

    CAS  PubMed  Google Scholar 

  8. Sakamaki S, Matsunaga T, Hirayama Y et al. Haematological study of healthy volunteers 5 years after G-CSF Lancet 1995 346: 1432 1433

    Article  CAS  PubMed  Google Scholar 

  9. Anderlini P, Körbling M, Dale D et al. Allogeneic blood stem cell transplantation: considerations for donors Blood 1997 90: 903 908

    CAS  PubMed  Google Scholar 

  10. Hasenclever D, Sextro M . Safety of alloPBSCT donors: biometrical considerations on monitoring long term risks Bone Marrow Transplant 1996 17: (Suppl. 2) S28 S30

    PubMed  Google Scholar 

  11. Bortin MM, D'Amaro J, Bach FH et al. HLA associations with leukemia Blood 1987 70: 227 232

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    P Anderlini, RE Champlin & M Körbling

  2. Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    FA Chan & SS Strom

Authors
  1. P Anderlini
    View author publications

    Search author on:PubMed Google Scholar

  2. FA Chan
    View author publications

    Search author on:PubMed Google Scholar

  3. RE Champlin
    View author publications

    Search author on:PubMed Google Scholar

  4. M Körbling
    View author publications

    Search author on:PubMed Google Scholar

  5. SS Strom
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anderlini, P., Chan, F., Champlin, R. et al. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant 30, 661–663 (2002). https://doi.org/10.1038/sj.bmt.1703693

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703693

Keywords

This article is cited by

Search

Advanced search

Quick links